Suppression of Experimental Autoimmune Encephalomyelitis by ILT3.Fc

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Cellular Immunology

Background:

• Multiple sclerosis (MS) is a chronic CNS autoimmune disease marked by demyelination and inflammation.
• Experimental autoimmune encephalopathy (EAE) in mice, induced by MOG35-55, models MS.
• Ig-like transcript 3 (ILT3) is an inhibitory receptor on tolerogenic dendritic cells.

Purpose of the Study:

• To investigate the therapeutic potential of recombinant human ILT3.Fc protein in a murine model of MS (EAE).
• To assess ILT3.Fc's ability to inhibit neuroinflammation and T-cell responses.

Main Methods:

• Administration of recombinant human ILT3.Fc protein to C57BL/6 mice with EAE.
• Measurement of proinflammatory cytokine release.
• Analysis of MOG35-55-specific Th1 and Th17 cell proliferation.
• Assessment of IFN-γ and IL-17A levels.
• Neuropathological examination of brain and spinal cord tissues.

Main Results:

• ILT3.Fc protein binds to murine immune cells and inhibits proinflammatory cytokine release.
• ILT3.Fc administration prevented rapid EAE disease progression and reduced Th1/Th17 cell proliferation.
• Inhibition of IFN-γ and IL-17A correlated with delayed disease onset and peak clinical score.
• Neuropathological analysis revealed reduced inflammation and demyelination in treated mice.

Conclusions:

• Inhibition of Th1 and Th17 cell development by ILT3.Fc effectively suppresses EAE.
• ILT3.Fc shows promise as a potential therapeutic agent for multiple sclerosis.
• Further research into ILT3.Fc's effects in other autoimmune models and cancer is warranted.